AstraZeneca surges to new 52-week high on better than expected Q1
Shares in AstraZeneca surged 5% to £119.3 closing in on a new 52-week high after first quarter revenue and earnings eclipsed market expectations and the pharmaceutical company reiterated full year guidance.
After a few months of consolidation, the shares are back to winning ways and outperforming the FTSE 100 year to date.
The pharma giant grew revenue 19% to $12.7 billion for the three m...